CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, cilt.17, sa.2, ss.211-221, 2019 (SCI-Expanded)
Objective: This study investigated changes in urotensin-II (U-II) and endocan levels which can be used as an early biological marker of endothelial injury in the episode and remission phases of bipolar affective disorder (BAD).